Global Liver Failure Market

Global Liver Failure Market Size Insights Forecasts to 2035

• The Global Liver Failure Market Size Was valued at USD 3.6 Billion in 2024
• The Global Liver Failure Market Size is Expected to Grow at a CAGR of around 7.16% from 2025 to 2035
• The Worldwide Liver Failure Market Size is Expected to Reach USD 7.7 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Liver Failure Market Size Was Worth Around USD 3.6 Billion In 2024 And Is Predicted To Grow To Around USD 7.7 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 7.16% From 2025 To 2035. The global liver failure market provides growth potential through advanced biologics and artificial liver support systems and rising transplant procedures and expanding regenerative medicine research and increasing alcohol-related liver cases and improved diagnostic technologies which are available worldwide.

 

Market Overview

Liver failure is a medical emergency that occurs when the liver loses its ability to carry out essential processes such as detoxifying substances and metabolizing compounds and synthesizing proteins. The global liver failure market is experiencing steady growth because liver diseases are becoming more common and people are drinking more alcohol and viral infections such as Hepatitis B and Hepatitis C continue to spread. Market growth receives support from government initiatives that focus on early diagnosis improvements and organ donation program expansion and healthcare infrastructure development. Many countries are also implementing awareness campaigns and funding research for advanced therapies and liver transplantation. The global liver failure market grows because healthcare systems receive financial support through regulatory policies that enable pharmaceutical companies and research institutions to create new treatment methods.

 

Report Coverage

This research report categorizes the liver failure market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the liver failure market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the liver failure market. 

 

Driving Factors

Liver failure constitutes a life-threatening medical disorder that results in complete loss of vital liver functions including detoxification and protein synthesis and metabolic processes. The Global Liver Failure Market refers to the worldwide market for treatments, diagnostics, and supportive care solutions used to manage acute and chronic liver failure. The market experiences growth because of increasing hepatitis infection cases and alcohol-related liver disease cases and non-alcoholic fatty liver disease (NAFLD) cases and drug-induced liver injury incidents. Countries worldwide are enhancing their liver disease management programs through national hepatitis elimination initiatives and public education campaigns and vaccination programs and better transplant system development. The global market expansion receives support from increased healthcare expenses and the establishment of more liver transplant centers and regulatory backing for new biologics and artificial liver support technologies.

 

Restraining Factors

Market growth faces multiple challenges because of high treatment and transplant costs combined with the shortage of donor organs and restricted healthcare access in low-income areas and the need for strict regulatory approvals and the occurrence of late-stage diagnosis and post-transplant complications and the lack of public knowledge.

 

Market Segmentation

The liver failure market share is classified into type, treatment type, and diagnosis.

 

• The chronic liver failure segment dominated the market in 2024, approximately 66% and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the liver failure market is divided into acute liver failure, chronic liver failure, and acute-on-chronic liver failure. Among these, the chronic liver failure segment dominated the market in 2024, approximately 66% and is projected to grow at a substantial CAGR during the forecast period. The increasing number of people who suffer from chronic liver diseases which include hepatitis B and C and alcoholic liver disease and non-alcoholic fatty liver disease NAFLD. The diseases cause ongoing harm to the liver which creates a demand for patients to receive constant medical care and monitoring. The segment maintains its dominant market position because of two factors which include the rising senior population and the growing number of hospital visits.

• The medications segment accounted for the largest share in 2024, approximately 50% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the treatment type, the liver failure market is divided into medications (antivirals, corticosteroids, supportive drugs), liver transplantation, artificial liver support systems, and others. Among these, the medications segment accounted for the largest share in 2024, approximately 50% and is anticipated to grow at a significant CAGR during the forecast period. The first-line treatment for liver failure and its hepatitis and inflammation and metabolic disorders. Antivirals and supportive drugs help slow disease progression and reduce complications. Medications are more accessible and cost-effective than transplantation. The segment growth receives support through ongoing pharmaceutical advancements and better treatment protocols.

 

• The blood tests segment accounted for the highest market revenue in 2024, approximately 55% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the diagnosis, the liver failure market is divided into blood tests, imaging (CT, MRI, ultrasound), and liver biopsy. Among these, the blood tests segment accounted for the highest market revenue in 2024, approximately 55% and is anticipated to grow at a significant CAGR during the forecast period. Physicians use liver function tests (LFTs) because these tests serve as their main diagnostic tool to identify liver damage. The tests provide an economical solution which requires little physical interruption to patients and has become a standard method for both screening and monitoring health conditions. Physicians use ALT and AST and bilirubin as biomarkers for initial disease identification. The segment experiences rapid expansion because of increased health check-ups and growing public understanding of health assessment practices.

 

Regional Segment Analysis of the Liver Failure Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the liver failure market over the predicted timeframe.

North America is anticipated to hold the largest share of the liver failure market over the predicted timeframe. The high rate of chronic liver diseases which includes hepatitis and alcoholic liver disease. The region achieves market leadership through its developed healthcare infrastructure and effective reimbursement systems which drive up liver transplantation rates and attract major pharmaceutical and biotechnology firms. The high rate of chronic liver diseases which includes hepatitis and alcoholic liver disease. The region achieves market leadership through its developed healthcare infrastructure and effective reimbursement systems which drive up liver transplantation rates and attract major pharmaceutical and biotechnology firms.

 

Asia-Pacific is expected to grow at a rapid CAGR in the liver failure market during the forecast period. The rising hepatitis B and C cases together with increasing alcohol-related liver disorders and the expanding elderly demographic drive this trend. The market expansion in China and India results from three factors which include better healthcare systems and improved diagnostic and transplantation service access and rising healthcare spending.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the liver failure market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Abbott Laboratories
• AbbVie Inc.
• Gilead Sciences Inc.
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Sanofi S.A.
• Astellas Pharma Inc.
• Bristol Myers Squibb
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the liver failure market based on the below-mentioned segments: 

 

Global Liver Failure Market, By Type

• Acute Liver Failure
• Chronic Liver Failure
• Acute-on-Chronic Liver Failure

 

Global Liver Failure Market, By Treatment Type

• Medications (antivirals, corticosteroids, supportive drugs)
• Liver Transplantation
• Artificial Liver Support Systems
• Others

 

Global Liver Failure Market, By Diagnosis

• Blood Tests
• Imaging (CT, MRI, Ultrasound)
• Liver Biopsy

 

Global Liver Failure Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected growth of the Global Liver Failure Market by 2035?

A: The market is projected to grow from USD 3.6 billion in 2024 to USD 7.7 billion by 2035, registering a CAGR of 7.16% during the forecast period 2025–2035.

 

2. Which segment dominated the market by type in 2024?

A: The chronic liver failure segment dominated in 2024, accounting for approximately 66% share due to rising hepatitis, NAFLD, and alcohol-related liver disease cases globally.

 

3. Why did the medications segment lead the treatment category?

A: Medications led with nearly 50% share in 2024 because they are first-line, cost-effective treatments that slow disease progression and are more accessible than transplantation procedures.

 

4. Which diagnostic method generated the highest revenue?

A: Blood tests accounted for about 55% revenue in 2024, as liver function tests are economical, minimally invasive, and widely used for screening and monitoring liver conditions.

 

5. Which regions are leading and fastest-growing?

A: North America holds the largest share due to advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region driven by rising hepatitis cases and expanding healthcare access.